MedTrace Logo

Study of ARO-HBV in Normal Adult Volunteers and Patients With Hepatitis B Virus (HBV)

NCT03365947 · Status: COMPLETED · Phase: PHASE1/PHASE2 · Type: INTERVENTIONAL · Enrollment: 114

Last updated 2025-10-22

Study results available
· View outcomes & findings →

Summary

The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics and pharmacodynamics of single- and multiple-ascending doses of ARO-HBV in healthy adult volunteers and participants with hepatitis B virus (HBV).

Conditions

Interventions

DRUG

ARO-HBV

sc injection

OTHER

Sterile Normal Saline (0.9% NaCl)

sc injection

DRUG

JNJ-56136379

oral tablets

Sponsors & Collaborators

  • Arrowhead Pharmaceuticals

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2018-03-27
Primary Completion
2020-04-23
Completion
2020-04-23
FDA Drug
Yes

Countries

  • Australia
  • Hong Kong
  • New Zealand

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03365947 on ClinicalTrials.gov